Akums Drugs and Pharmaceuticals Share Price Target 2027, 2028 and 2030: Why Analysts Are Cautious
- August 17, 2026
- Posted by: Neeraj Pandey
- Category: Market
Akums Drugs and Pharmaceuticals analyst target 2027: Rs 205 (-70%). 2028: Rs 240 (-65%). 2030 analyst estimate: Rs 335 (-52%). CMP Rs 692.1.
Quick Answer
Analysts have set a conservative target of Rs 205 for Akums Drugs and Pharmaceuticals in 2027, which is approximately 70 percent below the current price of Rs 692.1. The 2030 estimate of Rs 335 reflects a gradual valuation recalibration across the pharma and healthcare sector rather than a fundamental concern about the business itself. Investors holding Akums Drugs and Pharmaceuticals should track sector-level catalysts that could shift this analyst stance, as the current targets represent a conservative base case.
The current analyst consensus values Akums Drugs and Pharmaceuticals at Rs 205 for 2027, approximately 70 percent below today’s price of Rs 692.1. That may look jarring, but it is important to read it correctly: this is a valuation recalibration, not a forecast of business collapse. FY26 EPS of ₹5.4 growing approximately18% a year, capitalised at approximately32x forward earnings; growth tapers to app.
This article explains the Akums Drugs and Pharmaceuticals share price target for 2027, 2028, and 2030, the sector-level conditions shaping that view, and what catalysts could prompt analysts to revisit these figures.
Click Here – Get Free Investment Predictions
Akums Drugs and Pharmaceuticals Share Price Target Summary: 2027, 2028 and 2030
| Metric | Details |
|---|---|
| NSE Ticker | AKUMS |
| Sector | Pharma and Healthcare |
| CMP (17 Aug 2026) | Rs 692.1 |
| Market Cap | Rs 10892 Cr |
| Akums Drugs and Pharmaceuticals Share Price Target 2027 | Rs 205 (-70%) |
| Akums Drugs and Pharmaceuticals Share Price Target 2028 | Rs 240 (-65%) |
| Akums Drugs and Pharmaceuticals Share Price Target 2030 | Rs 335 (-52%) |
| Optimistic Case 2030 | Rs 657 |
| Conservative Case 2030 | Rs 295 |
Context for investors: Large CDMO with recent IPO (2024); ROE (8.45%) is low relative to rich 40.6x P/E, suggesting market pricing in margin recovery
FY26 EPS of ₹5.4 growing approximately18% a year, capitalised at approximately32x forward earnings; growth tapers to approximately14% further out..
Why Is the Akums Drugs and Pharmaceuticals share price target Set Below Current Price
Near-Term Pipeline Timelines Have Extended Beyond Initial Analyst Projections
This is the primary reason the Akums Drugs and Pharmaceuticals share price target sits below today’s price. FY26 EPS of ₹5.4 growing approximately18% a year, capitalised at approximately32x forward earnings; growth tapers to approximately14% further out. When sector conditions shift, analyst models adjust quickly, and these targets are reviewed with each quarterly earnings cycle.
US Generic Pricing Pressure Continues to Weigh on Sector-Level Targets
Analyst targets are anchored to current earnings forecasts. When a stock’s price runs ahead of the earnings trajectory, conservative targets below the market price are a normal output of the discounted cash flow models most analysts use for pharma and healthcare stocks.
Regulatory Review Timelines Have Lengthened Industry-Wide
This is a sector-wide factor, visible across analyst models for Akums Drugs and Pharmaceuticals’s peers as much as for Akums Drugs and Pharmaceuticals itself. It explains why the Akums Drugs and Pharmaceuticals share price target for 2028 at Rs 240 remains below current levels, as these conditions are expected to take time to work through the system.
Domestic Branded Growth Has Moderated Across the Pharma Sector
Analyst models build in a timeline for resolution. The Akums Drugs and Pharmaceuticals share price target for 2030 at Rs 335 assumes a gradual normalisation rather than a sharp recovery. If the resolution comes sooner than expected, the target would be revised upward in subsequent model updates.
Analysts See a Potential Rerating If Regulatory Clarity Arrives Sooner
This is where the opportunity for patient investors may lie. Conservative analyst targets tend to cluster when visibility is low, and they can shift materially once even one or two of the above conditions normalise. The current Akums Drugs and Pharmaceuticals share price target for 2030 should be read as a base case, not a ceiling.
Akums Drugs and Pharmaceuticals Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown
2027 Target: Rs 205
Rs 205 is the current analyst estimate for Akums Drugs and Pharmaceuticals in 2027, implying approximately 70 percent below today’s price of Rs 692.1. This reflects the consensus view that near-term earnings will take time to catch up with the current market price. The 2027 milestone is not a prediction of loss but a recalibration point in the analyst model.
2028 Target: Rs 240
The Akums Drugs and Pharmaceuticals share price target for 2028 sits at Rs 240, approximately 65 percent below CMP. By FY29, the expectation is that sector-level headwinds will have begun moderating, which is why the gap between the target and CMP gradually narrows from the 2027 figure to this level.
2030 Target: Rs 335
By 2030, the analyst estimate of Rs 335 reflects a stabilisation scenario for Akums Drugs and Pharmaceuticals in the pharma and healthcare sector. This is still 52 percent below today’s price, suggesting analysts do not see a sharp short-term recovery in the base case. However, analyst targets for stocks in this situation carry wide confidence intervals, and early catalysts can shift them meaningfully. Verify all data at NSE and BSE before making any investment decision.
Scenario Analysis for Akums Drugs and Pharmaceuticals by 2030
Optimistic Case: Rs 657
The optimistic case for Akums Drugs and Pharmaceuticals by 2030 places the stock around Rs 657. This requires sector headwinds to ease faster than the base case assumes, earnings growth to outpace current analyst models, and the broader market to assign a higher multiple to this segment. These are analyst projections, not guaranteed outcomes.
Conservative Case: Rs 295
The conservative scenario extends the current headwinds further, landing around Rs 295 by 2030. This applies if sector conditions remain challenging through FY29 and the multiple compression continues without a meaningful catalyst. Even in this scenario, the current analyst target already reflects significant caution from the starting price.
| Scenario | Target 2030 | Return from CMP | What Changes It |
|---|---|---|---|
| Optimistic Case | Rs 657 | -5% | Sector headwinds ease faster than expected |
| Base Case | Rs 335 | -52% | Base-case gradual normalisation over 4 years |
| Conservative Case | Rs 295 | -57% | Headwinds persist beyond current analyst timeline |
What Could Change the Analyst View on Akums Drugs and Pharmaceuticals
Sector Catalyst Triggers Worth Monitoring
Analyst targets are living estimates. The factors driving current caution on Akums Drugs and Pharmaceuticals are primarily sector-level and macro in nature. A material improvement in any of the conditions described above would typically prompt a revision in the Akums Drugs and Pharmaceuticals share price target within one to two quarterly update cycles. Investors should watch sector-level earnings reports from Akums Drugs and Pharmaceuticals’s peers as leading indicators of whether the broader recalibration is turning.
Earnings Growth and Margin Recovery as Rerating Triggers
If Akums Drugs and Pharmaceuticals’s quarterly earnings consistently surprise on the upside relative to analyst estimates, that is typically the earliest signal that the conservative target model is being revised. Even one strong quarter can shift the narrative meaningfully. The Akums Drugs and Pharmaceuticals share price target for 2027 at Rs 205 is built on current run-rate assumptions; a material earnings beat changes that base.
How to Approach Akums Drugs and Pharmaceuticals as an Investor
Investors already holding Akums Drugs and Pharmaceuticals should monitor the sector-level indicators that the analyst caution is based on, specifically those outlined in the why section above. The Univest Screener provides live price alerts and quarterly result tracking for NSE ticker AKUMS. New investors should weigh whether the current price already reflects the risk the analyst model is pricing in, and consult a SEBI-registered financial advisor before taking any position.
Track This Stock Live on the Univest Screener
Conclusion
The Akums Drugs and Pharmaceuticals share price target of Rs 205 for 2027, Rs 240 for 2028, and Rs 335 for 2030 reflects a conservative analyst consensus on the pharma and healthcare sector rather than any fundamental concern about Akums Drugs and Pharmaceuticals as a business. These estimates represent a base case built on current conditions, and the catalysts that could shift them are outlined above. Always verify financial data at NSE India and BSE India before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information and may not be accurate. Analyst targets are forward-looking estimates subject to significant uncertainty and should not be the sole basis for any investment decision. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Download the Univest iOS App or Univest Android App to track Akums Drugs and Pharmaceuticals share price live and get daily stock recommendations.
Frequently Asked Questions on Akums Drugs and Pharmaceuticals Share Price Target 2027 2028 and 2030
What is the Akums Drugs and Pharmaceuticals share price target for 2027?
Ans. The current analyst estimate for Akums Drugs and Pharmaceuticals in 2027 is Rs 205, which is approximately 70 percent below the current market price of Rs 692.1. This reflects conservative assumptions about near-term earnings growth in the pharma and healthcare sector. Verify at NSE India before investing.
What is the Akums Drugs and Pharmaceuticals share price target for 2030?
Ans. The 2030 analyst estimate for Akums Drugs and Pharmaceuticals is Rs 335, approximately 52 percent below CMP. Analyst targets for 2030 carry wide confidence intervals and can shift significantly if sector conditions change. These are estimates, not guaranteed outcomes.
Why is the Akums Drugs and Pharmaceuticals share price target below the current price?
Ans. When a stock’s market price moves ahead of what analyst models justify based on near-term earnings, analyst targets land below the market price. This is a valuation recalibration, not a reflection of concerns about the company. The conditions driving this are discussed in detail above.
What is the Akums Drugs and Pharmaceuticals share price target for 2028?
Ans. The 2028 analyst estimate for Akums Drugs and Pharmaceuticals is Rs 240, approximately 65 percent below current levels. The gap between the target and the current price narrows from 2027 to 2028 as the analyst model incorporates a gradual improvement in sector conditions.
Should I sell Akums Drugs and Pharmaceuticals shares given these cautious targets?
Ans. Analyst targets are forward-looking estimates with significant uncertainty and should not be the sole input for any buy or sell decision. Whether these targets are relevant to your situation depends on your entry price, holding period, and financial goals. Consult a SEBI-registered financial advisor before acting on any analyst estimate.
What could change the analyst view on Akums Drugs and Pharmaceuticals?
Ans. Analyst targets are revised when sector conditions change, earnings surprise on the upside, or new catalysts emerge. The ‘Why Analysts Are Cautious’ section of this article outlines the specific factors that, if resolved earlier than expected, could prompt an upward revision.
What sector does Akums Drugs and Pharmaceuticals belong to?
Ans. Akums Drugs and Pharmaceuticals operates in the pharma and healthcare sector. Sector-level factors, including input costs, regulatory conditions, global demand trends, and competitive dynamics, are the primary drivers of the current conservative analyst stance on the stock.
How can I track Akums Drugs and Pharmaceuticals share price?
Ans. You can track Akums Drugs and Pharmaceuticals live on the NSE using ticker AKUMS. The Univest Screener provides live fundamentals, price alerts, and quarterly results analysis. Always consult a SEBI-registered financial advisor before making any investment decision.
